Position of the Transparency Council – Minjuvi (tafasitamab)
At its meeting on 22 April 2025, the Transparency Council adopted position No. 47/2025 on the evaluation of the drug Minjuvi (tafasitamab) under the B.12.FM drug program treatment of patients with B-cell lymphomas (ICD-10: C82, C83, C85)